0001225208-18-000838.txt : 20180108
0001225208-18-000838.hdr.sgml : 20180108
20180108164356
ACCESSION NUMBER: 0001225208-18-000838
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20180101
FILED AS OF DATE: 20180108
DATE AS OF CHANGE: 20180108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wang Xin Warren
CENTRAL INDEX KEY: 0001725283
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 18516891
MAIL ADDRESS:
STREET 1: C/O BOSTON SCIENTIFIC CORPORATION
STREET 2: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
3
1
doc3.xml
X0206
3
2018-01-01
0
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001725283
Wang Xin Warren
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH
MA
01752-1234
1
SVP and Pres, Asia Pacific
Common Stock
92531.0000
D
Deferred Stock Units
2020-02-23
Common Stock
6346.0000
D
Deferred Stock Units
2019-02-24
Common Stock
5276.0000
D
Deferred Stock Units
2018-02-28
Common Stock
9337.0000
D
Deferred Stock Units
2022-02-28
Common Stock
8146.0000
D
Deferred Stock Units
2019-10-27
Common Stock
3052.0000
D
Deferred Stock Units
2018-10-29
Common Stock
2545.0000
D
Deferred Stock Units
2020-12-01
Common Stock
6075.0000
D
Stock Option (Right to Buy)
13.0800
2024-02-24
Common Stock
34500.0000
D
Stock Option (Right to Buy)
16.3100
2025-02-23
Common Stock
32003.0000
D
Stock Option (Right to Buy)
18.5200
2025-12-01
Common Stock
30637.0000
D
Stock Option (Right to Buy)
24.5500
2027-02-28
Common Stock
28860.0000
D
Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 23, 2015, which will continue to vest in three remaining installments on the anniversary of the date of grant.
Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 24, 2014, which will continue to vest in two remaining installments on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on February 28, 2013, which will continue to vest in one remaining installment on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 27, 2015, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on October 27, 2014, which will continue to vest in two remaining installments on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 29, 2014, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on October 29, 2013, which will continue to vest in one remaining installment on the anniversary of the date of grant.
Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant.
This amount represents the unvested portion of DSUs awarded on December 1, 2015, which will continue to vest in three remaining installments on the anniversary of the date of grant.
Grant to the reporting person of an option to purchase a 34,500 shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase a 32,003 shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase a 30,637 shares of common stock vesting in four equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant.
Grant to the reporting person of an option to purchase a 28,860 shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
wangpoa.txt
/s/ Vance R. Brown, Attorney-in-fact
2018-01-08
EX-24
2
wangpoa.txt
POWER OF ATTORNEY
Know all by these present that the undersigned hereby constitutes and
appoints each of Desiree Ralls-Morrison, Vance R. Brown, Jeff Mann, Ashley E.
McGrane and Mai-KhoiNguyen-Thanh signing singly, the undersigned's true and
lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an executive officer and/or director of Boston Scientific
Corporation
(the "Company"), Forms 3, 4 and 5, and amendments thereto, in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5
and file such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority;
(3) execute for and on behalf of the undersigned, in the undersigned's capacity
as an executive officer and/or director of the Company, Forms 144 in accordance
with Rule 144 of the Securities Exchange Act of 1933, as amended and the rules
and regulations thereunder; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might
or could do if personally present, with full power of substitution or
revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities
Act of 1933, as amended.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with
respect to the undersigned's holdings of and transactions in securities issued
by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 7th day of December, 2017.
/s/ Xin Warren Wang
________________
Xin Warren Wang